A detailed history of Ausdal Financial Partners, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Ausdal Financial Partners, Inc. holds 6,655 shares of GILD stock, worth $586,172. This represents 0.06% of its overall portfolio holdings.

Number of Shares
6,655
Previous 6,921 3.84%
Holding current value
$586,172
Previous $474,000 17.51%
% of portfolio
0.06%
Previous 0.05%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 04, 2024

SELL
$66.59 - $83.99 $17,712 - $22,341
-266 Reduced 3.84%
6,655 $557,000
Q2 2024

Aug 06, 2024

BUY
$63.15 - $72.88 $2,210 - $2,550
35 Added 0.51%
6,921 $474,000
Q1 2024

Apr 12, 2024

SELL
$71.58 - $87.29 $58,337 - $71,141
-815 Reduced 10.58%
6,886 $504,000
Q4 2023

Jan 11, 2024

SELL
$73.27 - $83.09 $21,614 - $24,511
-295 Reduced 3.69%
7,701 $623,000
Q3 2023

Nov 08, 2023

BUY
$73.94 - $80.67 $42,663 - $46,546
577 Added 7.78%
7,996 $599,000
Q2 2023

Jul 31, 2023

BUY
$76.01 - $86.7 $17,026 - $19,420
224 Added 3.11%
7,419 $571,000
Q1 2023

May 04, 2023

BUY
$77.31 - $88.08 $3,865 - $4,404
50 Added 0.7%
7,195 $596,000
Q4 2022

Feb 03, 2023

BUY
$62.32 - $89.47 $13,523 - $19,414
217 Added 3.13%
7,145 $613,000
Q3 2022

Nov 09, 2022

SELL
$59.54 - $68.01 $2,202 - $2,516
-37 Reduced 0.53%
6,928 $427,000
Q2 2022

Aug 09, 2022

SELL
$57.72 - $65.01 $25,858 - $29,124
-448 Reduced 6.04%
6,965 $430,000
Q1 2022

May 04, 2022

SELL
$57.92 - $72.58 $405 - $508
-7 Reduced 0.09%
7,413 $441,000
Q4 2021

Feb 08, 2022

SELL
$64.88 - $73.64 $22,124 - $25,111
-341 Reduced 4.39%
7,420 $539,000
Q3 2021

Nov 01, 2021

SELL
$67.69 - $73.03 $22,066 - $23,807
-326 Reduced 4.03%
7,761 $542,000
Q2 2021

Jul 19, 2021

BUY
$63.47 - $69.35 $36,241 - $39,598
571 Added 7.6%
8,087 $557,000
Q1 2021

May 05, 2021

BUY
$60.0 - $68.46 $57,900 - $66,063
965 Added 14.73%
7,516 $486,000
Q4 2020

Feb 01, 2021

BUY
$56.65 - $64.55 $77,440 - $88,239
1,367 Added 26.37%
6,551 $382,000
Q3 2020

Nov 04, 2020

SELL
$62.1 - $78.08 $39,433 - $49,580
-635 Reduced 10.91%
5,184 $328,000
Q2 2020

Aug 06, 2020

BUY
$72.34 - $84.0 $26,548 - $30,828
367 Added 6.73%
5,819 $448,000
Q1 2020

May 04, 2020

BUY
$62.63 - $80.22 $15,657 - $20,055
250 Added 4.81%
5,452 $443,000
Q4 2019

Feb 14, 2020

SELL
$61.62 - $67.78 $68,706 - $75,574
-1,115 Reduced 17.65%
5,202 $334,000
Q2 2019

Aug 05, 2019

SELL
$61.87 - $69.38 $36,503 - $40,934
-590 Reduced 8.54%
6,317 $424,000
Q1 2019

May 13, 2019

BUY
$62.53 - $70.05 $38,268 - $42,870
612 Added 9.72%
6,907 $449,000
Q4 2018

Feb 11, 2019

SELL
$60.54 - $79.0 $57,452 - $74,971
-949 Reduced 13.1%
6,295 $394,000
Q3 2018

Nov 09, 2018

SELL
$71.28 - $78.92 $54,956 - $60,847
-771 Reduced 9.62%
7,244 $559,000
Q2 2018

Aug 08, 2018

BUY
$64.88 - $75.68 $16,414 - $19,147
253 Added 3.26%
8,015 $568,000
Q1 2018

Apr 20, 2018

BUY
$72.84 - $88.8 $15,442 - $18,825
212 Added 2.81%
7,762 $585,000
Q4 2017

Feb 08, 2018

SELL
$71.15 - $83.52 $3,557 - $4,176
-50 Reduced 0.66%
7,550 $541,000
Q3 2017

Oct 31, 2017

BUY
$72.11 - $85.47 $548,036 - $649,572
7,600
7,600 $616,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $110B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Ausdal Financial Partners, Inc. Portfolio

Follow Ausdal Financial Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ausdal Financial Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ausdal Financial Partners, Inc. with notifications on news.